Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72(6):1987–99.

Article  CAS  PubMed  Google Scholar 

Yugawa K, Maeda T, Nagata S, Sakai A, Edagawa M, Omine T, et al. A novel combined prognostic nutritional index and aspartate aminotransferase-to-platelet ratio index-based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection. Surg Today. 2022;52(7):1096–108.

Article  CAS  PubMed  Google Scholar 

Matsumoto T, Kitano Y, Imai K, Kinoshita S, Sato H, Shiraishi Y, et al. Clinical significance of preoperative inflammation-based score for the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy. Surg Today. 2022;52(7):1008–15.

Article  CAS  PubMed  Google Scholar 

Iseda N, Itoh S, Toshida K, Nakayama Y, Ishikawa T, Tsutsui Y, et al. Impact of albumin-lymphocyte-platelet-C-reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: associated with nuclear factor erythroid 2-related factor 2. Hepatol Res. 2024;54(1):91–102.

Article  CAS  PubMed  Google Scholar 

Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Shimagaki T, et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Int J Clin Oncol. 2021;26(10):1890–900.

Article  CAS  PubMed  Google Scholar 

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66.

Article  PubMed  PubMed Central  Google Scholar 

Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.

Article  PubMed  Google Scholar 

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–62.

Article  CAS  PubMed  Google Scholar 

Toshida K, Itoh S, Yoshiya S, Nagao Y, Tomino T, Izumi T, et al. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2024;39(3):576–86.

Article  CAS  PubMed  Google Scholar 

Iseda N, Itoh S, Toshida K, Tomiyama T, Morinaga A, Shimokawa M, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 2022;113(7):2272–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hidaka M, Hara T, Soyama A, Sasaki R, Matsushima H, Tanaka T, et al. The outcome of conversion liver resection surgery by lenvatinib treatment: a single center experience. Anticancer Res. 2022;42(6):3049–54.

Article  PubMed  Google Scholar 

Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28(12):7663–72.

Article  PubMed  Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

Article  CAS  PubMed  Google Scholar 

Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, et al. Impact of metabolic activity in hepatocellular carcinoma: association with immune status and vascular formation. Hepatol Commun. 2021;5(7):1278–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, et al. conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43(2):943–7.

Article  PubMed  Google Scholar 

Hidaka Y, Tomita M, Desaki R, Hamanoue M, Takao S, Kirishima M, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20(1):228.

Article  PubMed  PubMed Central  Google Scholar 

Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, et al. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol. 2021;13(3):384–92.

Article  PubMed  PubMed Central  Google Scholar 

Itoh S, Toshida K, Morita K, Kurihara T, Nagao Y, Tomino T, et al. Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. Int J Clin Oncol. 2022;27(11):1725–32.

Article  CAS  PubMed  Google Scholar 

Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwara M, et al. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12(11):12325–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen QF, Chen S, Chen M, Lyu N, Zhao M. Improving the conversion success rate of hepatocellular carcinoma: focus on the use of combination therapy with a high objective response rate. J Clin Transl Hepatol. 2024;12(3):298–304.

CAS  PubMed  PubMed Central  Google Scholar 

Liang C, He Z, Tao Q, Tang X, Jiang L, Tu X, et al. From conversion to resection for unresectable hepatocellular carcinoma: a review of the latest strategies. J Clin Med. 2023;12(24):7665.

Article  CAS  PubMed  PubMed Central  Google Scholar